Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT536 in Recurrent WHO Grade 4 Astrocytoma
NCT07560865Phase 1Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT536 in astrocytoma (3 cohorts), sponsored by Masonic Cancer Center. Primary endpoint: Safety and Tolerability at 1 year. Started Apr 2026; status: recruiting.
02
Drugs
FT536
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT07560865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560865.